Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

The Agreement is an LOI to in-license Ph. II drug candidate L-Dopa-Induced Dyskinesia PD from an undisclosed 3rd party - one of several suggested Pharma's:

http://biz.yahoo.com/e/130613/ambs8-k.html

1.) Endo Pharmaceuticals (Amantadine)
2.) Adamas Pharmaceuticals (Nurlin)
3.) Novartis Pharmaceuticals (Mavoglurant)
4.) Addex Therapeutics (Dipraglurant)
5.) Psychogenics Pharmaceuticals (Eltoprazine)
6.) Avanir Pharmaceuticals (Nuedexta)
7.) Neurim Pharmaceuticals (Neu-120)

Safe to say Avanir Pharmaceuticals (Nuedexta) was eliminated?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93244937

If so, that leaves 6 remaining.

JN suspects #4 - Addex Therapeutics and their Phase IIb ready drug candidate, Dipraglurant for LID to be a potential AMBS LOI candidate.

http://scr.zacks.com/files/June%2019%202013_AMBS_Napodano_v001_n50g1c.pdf

I say #3 - Novartis - for way too many reasons already cited on the thread by many.